Interferon Gamma 13-CA-Repeat Homozygous Genotype and a Low Proportion of CD4+ Lymphocytes Are Independent Risk Factors for Cytomegalovirus Reactivation with a High Number of Copies in Hematopoietic Stem Cell Transplantation Recipients  by Jaskula, Emilia et al.
From the
menta
and 2
Natio
Financial d
Correspon
of Im
Scien
12, 53
Received F
 2009 Am
1083-8791
doi:10.101
1296Interferon Gamma 13-CA-Repeat Homozygous
Genotype and a Low Proportion of CD41 Lymphocytes
Are Independent Risk Factors for Cytomegalovirus
Reactivation with a High Number of Copies in
Hematopoietic Stem Cell Transplantation Recipients
Emilia Jaskula,1 Dorota Dlubek,1,2 Dorota Duda,2 Katarzyna Bogunia-Kubik,1
Anna Mlynarczewska,1 Andrzej Lange1,2Cytomegalovirus (CMV) reactivation was analyzed in 92 recipients of allogeneic hematopoietic stem cell
transplantation (HSCT) in relation to the proportion of CD41 lymphocytes in blood and a microsatellite
polymorphism within the first intron of the interferon-gamma (IFNG) gene. CMV reactivation was found
in 50% of the HSCT recipients; in 30% of these individuals, the level of CMV copies exceeded 100 per 105
peripheral blood (PB) cells on at least one occasion during the 100-day post-HSCT observation period.
This high CMV copy level was most frequently found between 31 and 60 days post-HSCT (P5.021). Patients
with $ 100 CMV copies/105 cells were characterized by poorer overall survival (OS) compared with those
lacking CMV copies or having\ 100 CMV copies/105 cells (P 5 .04), and they suffered from severe post-
HSCT complications, including acute graft-versus-host disease (aGVHD) and relapse. Thus, patients with
$ 100 CMV copies/105 cells were designated as having clinically significant CMV reactivation. Patients
with\ 10% CD41 lymphocytes had a higher number of CMV DNA copies than those with higher propor-
tions of CD41 lymphocytes (0.62 vs 0.21, P5.001; mean6 SEM, 44226 1667 vs 9376 662 CMV copies/105
cells, P\.001, for the proportion of cases with reactivation and numbers of copies, respectively). Similarly,
patients carrying 2 IFNG 13-CA-repeat alleles (homozygotes) had more frequent CMV reactivation (0.50 vs
0.26; P5 .039) and a higher CMV load (41116 1699 vs 9506591 CMV copies/105 cells; P5 .041) compared
with those with other IFNG microsatellite allele constellations. Multivariate analysis demonstrated that the
IFNG 13-CA-repeat homozygous genotype (odds ratio [OR] 5 0.221; P 5 .044), a low proportion of
CD41 lymphocytes (OR5 0.276; P5.050), and a lack of optimal (10/10 alleles) donor–recipient HLAmatch
(OR 5 15.19; P 5 .006) were independent risk factors for CMV reactivation with a high number of copies.
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anti-CMV antibodies, which result from previous
exposure to CMV [1]. Following the initial exposure,
CMV resides in the host cells and is controlled by
the T cell immune response. CMV reactivation occurs
most frequently in immunosuppressed individuals,
including those receiving hematopoietic stem cells
(HSCs). CMV reactivation is associated with 30% of
cases of CMV infection; these cases usually respond
poorly to treatment and carry a high mortality rate [2].
Interferon-gamma (IFNG) is an antiviral factor
that exerts an inflammatory response against CMV-in-
fected cells [3]. IFNG generation potential is corre-
lated with the number and proportion of CD41
lymphocytes [4]. Moreover, IFNG production is
known to be influenced by some HLA-associated fea-
tures and also by IFNG gene polymorphism [5,6]. Two
Table 1. Patient Characteristics
Number of patients 92
Age, years, median (range) 33 (1-60)
Adults (age > 16 years) 80
Children (age < 16 years) 12
Recipient sex
Female 49
Male 43
Donor
Sibling 45
HLA-matched (10/10) unrelated 35
MUD 12
Transplant material
BM 14
PBPCs 78
Diagnosis
Hematologic malignancies 78
Chronic myelogenous leukemia 11
Chronic lymphocytic leukemia 3
Acute myelogenous leukemia 25
Acute lymphoblastic leukemia 10
Other 29
Anemias and immunodeficiences 14
Conditioning regimen
Myeloablative 36
RIC 56
aGVHD, grades
0 43
I 14
II 15
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phism (A/T) within the first intron of the IFNG gene at
position1874 from the translation start site and amicro-
satellite polymorphism of CA repeats (11-15) starting at
position 1875—are closely linked to one another.
Good IFNG producers are considered to be individuals
with 12 CA repeats and a T at the polymorphic site
[7,8]. Other microsatellite alleles are associated with the
presence of A, but it seems that only those with 13 repeats
have rather low IFNG generation potential [9,10]. The
literature contains conflicting reports with respect to
this observation, however [11]; in other words, whether
a microsatellite polymorphism or the presence of an A/
T transition can influence the gene transcription, thus
making an individualmore or less adept at IFNGproduc-
tion, remains up for debate. In the present study, we iden-
tified patients who were more susceptible to CMV
reactivation than those receiving transplants from donors
not optimallymatched at the allelic level and having a low
CD41 lymphocyte proportion and count. We found
a significant association between recipient low IFNG
generation microsatellite genotype (13-CA-repeats) and
the risk of CMV reactivation at a clinically relevant level.III 10
IV 10
Chronic GVHD
Extensive 25
Limited 11
CMV $100 DNA copies /105 cells 28
CMV IgG serostatus
Recipient
CMV IgG negative 8
CMV IgG positive 81
Donor
CMV IgG negative 24
CMV IgG positive 64
HSCT
Recipient IgG (+)/donor IgG(-) 21
Recipient IgG (-)/donor IgG(+) 5
MUD indicates matched unrelated donor; BM, bone marrow; PBPCs,
peripheral blood progenitor cells; aGVHD, acute graft-versus-host dis-
ease; RIC, reduced intensity conditioning; HSCT, hematopoietic stem
cell transplantation; CMV, cytomegalovirus.PATIENTS AND METHODS
Patient Characteristics
Over a 4-year period (2004-2008), 92 patients
underwent HSC transplantaion (HSCT) (45 with
a transplant froma siblingdonor and47witha transplant
from an alternative donor). Conditioning regimens that
included antithymocyte globulin (ATG) or Campath
(Table 1) were applied to 70 patients who also received
gancyclovir during the conditioning regimen to counter
the increased risk of viral reactivation [12]. All patients
with $ 100 CMV copy numbers/105 peripheral blood
(PB) cells (except 3 with a smooth post-HSCT course)
were given a 14-day course of gancyclovir.
All patients were routinely followed up with respect
to clinical complications and blood tests, including the
proportions of CD41 lymphocytes in blood and the
number of CMV DNA copies. The latter analyses were
performed at 1-week intervals until 30 days post-
HSCT, then monthly until 100 days post-HSCT, as
well as when clinical symptoms were suggestive of
CMVreactivation (ie, feverofunknownorigin associated
with marrow depression and/or elevated aminotransfer-
ases). The number of measurements obtained varied
from 3 to 27 (median, 8). Patients with higher numbers
of measurements were usually positive for CMV copies
and were further followed to monitor the effect of the
preemptive treatment. Thus, a lower number of mea-
surements reflects a smooth post-HSCT course. Four-
teen patients died before 100 days post-HSCT; of
these, 9 were positive for herpes virus reactivation.The peak value of CMV copies aids in dividing
patients into 2 subgroups: those withmild viremia usu-
ally not associated with apparent clinical complications
and those with viremia at a level strongly associated
with complications. Altogether, of the 92 patients in
the study group, 46 were CMV-positive, and 28 of
them had peak viremia exceeding 100 CMV DNA
copies/105 cells. Clinical observations provided all
pertinent information regarding immunosuppression
and transplantation-related morbidity. Genetic data
included microsatellite IFNG genotyping.DNA Isolation and IFNG (CA)n Microsatellite
Polymorphism Detection
DNAwas extracted from PB using a QiAmp Blood
Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. IFNG microsatellite
1298 Biol Blood Marrow Transplant 15:1296-1305, 2009E. Jaskula et al.polymorphism was analyzed as described previously
[13]. In brief, a portion of the first intron of the
IFNG gene, containing the (CA)n microsatellite re-
gion, was amplified using the TAMRA-labeled for-
ward (5’-GCT GTC ATA ATA ATA TTC
AGA C-3’) and reverse (5’-CGA GCT TTA AAA
GAT AGT TCC-3’) primers. After denaturation at
95C for 5 minutes, all of the samples were analyzed
on 6%polyacrylamide gel with 7Murea (Gibco, Paisley,
UK) with an ABI 377 automated DNA sequencer
(Applied Biosystems, Foster City, CA). Electrophoresis
was carried out at 3000 V and 51C. Genescan 3.1.2
software (Applied Biosystems) was used to analyze
the electrophoretic patterns.
CMV DNA Quantification
The number of CMV DNA copies in PB cells was
determined by real-time polymerase chain reaction
(PCR) using the Opticon 2 system (MJ Research,
Watertown, MA). The sequences of the PCR primers
and the probe were selected from the US17 region of
CMV, and PCR was carried out as described by Ma-
chida et al. [14]. For a quantitative analysis of the num-
ber of CMV copies, a CMV standard was prepared by
inserting the US17 CMV gene fragment encoding vi-
ral DNA polymerase into a pCR 2$1 cloning vector
(Invitrogen, Carlsbad, CA). A standard 5-point curve
was obtained using serial dilutions (from 0 to 2.3 
105 copies) of these CMV standards.
The initial number of blood cells and the number
of b-actin copies were assessed for the quantification
of the isolated DNA. This analysis was performed
using a b-actin TaqMan Endogenous Control Kit
(Eurogentec, Seraind, Belgium) according to the man-
ufacturer’s instructions. A 5-point b-actin standard
curve was prepared using a serially diluted (from 0 to
1 104 copies) human Xsomal DNA control provided
with the Eurogentec kit. The number of CMVgenomic
copies was calculated and related to the b-actin copies
proportionally referring to 105 whole blood cells
(WBCs).
Clinical Observation and Blood Phenotypic
Analysis
Treatment-related toxicity and acute graft-versus-
host disease (aGVHD) were diagnosed according to
our standard operation procedure based on
internationalGVHDdiagnosis and stagingcriteria [12].
Residual disease and immunologic recovery were
determined by flow cytometry. The panel of monoclo-
nal antibodies (mAbs) for the detection of lymphocyte
populations was purchased from Becton-Dickinson
(San Jose, CA). A CD45mAbwas used to gate the lym-
phocyte populations. The cells were analyzed using
a FACScalibur Flow Cytometer (Becton-Dickinson),
using CellQuest software for data acquisition, and thedata were analyzed using WinMDI 2.8 software. In
most cases, 20,000 cells were acquired in the lympho-
cyte gate.
Retrospective analysis of the 92 patients revealed
that those individuals with at least 100 copies of
CMV DNA per 105 cells on one occasion suffered
more frequently from post-HSCT complications,
including sepsis, hepatitis, encephalitis, cystitis, pneu-
monia, hemolytic anemia or pure red cell aplasia,
relapse or marrow failure, and/or aGVHD grade
$ II, compared with those with absent or lower num-
bers of CMV DNA copies (0.46 vs 0.16; P 5 .013).
This analysis does not prove that CMV is directly
involved in the pathological mechanism of the afore-
mentioned transplantation complications, but suggests
an association between the presence of $ 100 CMV
copies per 105 PB cells and post-HSCT morbidity.
Therefore, 100 CMV DNA copies per 105 PB cells
was chosen as the threshold indicating clinical signifi-
cance. Indeed, the survival curves of patients having
or lacking CMV reactivation at the level of$ 100 cop-
ies/105 cells differed significantly in favor of the latter
group,with 41%and71% (P5 .040) of individuals sur-
viving to 3 years post-HSCT, respectively.
Statistical Analysis
Statistical analysis was performed using CSS Sta-
tistica for Windows version 7.0 (Sta-Soft, Tulsa,
OK). Univariate analyses of the IFNG genotype distri-
bution in patients having or lacking CMV reactivation
were performed using Fisher’s exact test. The Mann-
Whitney U test or Kruskal-Wallis nonparametric
analysis of variance (ANOVA) were used to compute
the differences between 2 or more independent patient
groups, respectively. Factorial ANOVA was used to
assess the possible association of 2 or more factors
and logistic regression for multivariate analysis. Dif-
ferences between samples were considered significant
when P\ .05.RESULTS
CMV reactivation ($ 100 CMV DNA copies/105
PB cells) was observed in 28 of the 92HSCT recipients
(30%) and was more frequent in those with\ 10%
CD41 lymphocytes compared with those with a higher
percentage of CD41 lymphocytes in the blood (0.62 vs
0.21; P5 .001). The patients with\10% CD41 lym-
phocytes also had higher copy numbers than those
with a higher percentage of CD41 lymphocytes
(mean6 SEM, 4422 6 1667 vs 937 6 662 CMV cop-
ies/105 cells; P\ .001). In addition, CMV reactivation
with a higher number of copies was observed more of-
ten in patients (1) receiving a graft from not optimally
matched donors (at a level below 10/10 HLA alleles)
(0.67 vs 0.30; P 5 .008), (2) having aGVHD grade . I
Table 2. Univariate Analysis of Risk Factors for CMV Reactivation*
Cases with the Given Factor among Patients
Factor CMV Reactivation
Lack of CMV
Reactivation P Value
Recipient IFNG genotype Homozygous 13-CA-repeat genotype 11 11 .039
Others 18 52
aGVHD Lack of aGVHD 12 31 .273
aGVHD 20 29
aGVHD grade $ II Lack of aGVHD or aGVHD grade I 12 39 .075
aGVHD grade $ II 17 24
Conditioning regimen Myeloablative 12 24 .820
RIC 17 39
Type of donor MUD 18 30 .262
Sibling 11 33
Recipient age <16 years 2 10 .327
$ 16 years 27 53
Recipient CMV IgG CMV IgG negative 2 6 .593
CMV IgG positive 26 55
Donor CMV IgG CMV IgG negative 10 15 .453
CMV IgG positive 19 44
Donor-recipient IgG CMV serology mismatch Mismatched (D+/R-, D-/R+) 12 14 .083
Matched (D+/R+, D-/R-) 16 45
D-/R+ 10 12 .185
D+/R+, D-/R-, D+/R- 18 47
D-/R+ 2 2 .598
D+/R+, D+/R-, D-,R+ 27 56
Donor sex Female 8 32 .044
Male 21 31
Recipient sex Male 14 35 .653
Female 15 28
Source of HSCT BM 5 9 .534
PBPC 21 54
CD4+ lymphocytes < 10% 13 9 .001
$ 10% 14 53
HLA mismatch Matched (10/10) 21 59 .008
Mismatched 8 4
Donor/recipient sex Matched (female to female or male to male) 17 44 .345
Mismatched (female to male or male to female) 12 19
Female to male 2 8 .496
Male to male, female to female, and male to
female
27 55
Male to female 9 11 .176
Male to male, female to female, and female to
male
20 52
D+ indicates donor CMV IgG positive; D–, donor CMV IgG negative; R–, recipient CMV IgG negative; R+, recipient CMV IgG positive.
*CMV reactivation was defined as the presence of $ 100 CMV DNA copies/105 peripheral blood cells.
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CMV IgG serostatus from that of the donor (0.46 vs
0.26; P 5 .083) (Table 2).
In total, 22 (24%) and 16 (17%) patients were
homozygotes carrying 13 CA repeats (allele 3) and 12
CA repeats (allele 2) in the first intron of the IFNG
gene, respectively.The rest of the patients were hetero-
zygous for 12, 13, or more CA repeats. Compared with
patients with other allele constellations, patients
homozygous for the 13-CA-repeat IFNG genotype
(IFNG 3/3 genotype) had higher peak values of CMV
copies (4111 6 1699 vs 950 6 591 CMV copies/105
cells; P 5 .041) and experienced more CMV reactiva-
tion 0.5 vs 0.26; P5 .039) (Figure 1A). These findings
were seen in patients receiving myeloablative (MA)
conditioning as well as in those receiving reduced-in-
tensity conditioning (RIC); however, the difference
was statistically significant only in the latter group(5873 6 2374 vs 1092 6 984 CMV copies/105 cells, P
5 .001; 0.67 vs 0.17, P\ .001).
By univariate analysis, recipient sex, donor–recipi-
ent sex relation, type of donor (sibling or matched
unrelated donor [MUD]), conditioning regimen (MA
or RIC), CMV IgG donor and recipient serostatus,
and recipient age had no significant influence on the
risk of CMV reactivation (Table 2).
To evaluate the impact of genotypes composed of
alleles with more than 13 repeats, the incidence of
CMV reactivation in homozygotes carrying 13-CA
repeats (allele 3) was compared with those carrying
one 13-repeat allele as well as a second allele composed
of more than 13 repeats. (Patients in both groups were
homozygous for the presence of A at the polymorphic
site.) The homozygotes for 13-CA repeats had CMV
reactivation in 50% of cases; however, CMV reactiva-
tion was observed in only 14% of the cases in which the
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Figure 1. Relationship between the recipient IFNG polymorphism and the number of CMV copies and the incidence of CMV reactivation after HSCT
(A) and the percentage of CD41 lymphocytes (B).
1300 Biol Blood Marrow Transplant 15:1296-1305, 2009E. Jaskula et al.patient had one allele with 13 repeats and another
allele with more than 13 repeats (P5 .18), even though
all of these patients were homozygotes for A at the
IFNG 1874 SNP site. Moreover, heterozygotes with
respect to the CA-repeat polymorphism had less fre-
quent reactivation of CMV compared with homozy-
gotes for 13-CA-repeats (0.26 vs 0.50; P 5 .059).
Patients carrying the 13-CA-repeat homozygous
IFNG genotype hadmore frequent viremia ($ 100 cop-
ies/105 cells) for longer than 30 days compared with
those with other allele constellations (0.72 vs 0.24;
P 5 .019). In this group of homozygous patients,
CMV viremia occurred early post-HSCT. Nine of
the 22 13-CA-repeat IFNG genotype homozygotes,but only 12 of the 70 recipients with other alleles,
were positive for CMV copies by 30 days post-HSCT
(P 5 .038).
CMV seropositivity of the recipients was predictive
of the riskofCMVviremia.Toexclude thebias between
HLAmatching andCMVseropositivity in assessing the
role of IFNG genotype as a risk factor of CMV reactiva-
tion, a subgroupofCMV-seropositive patientswhoalso
were fully HLA-matched was evaluated. In this group,
the 13-CA-repeat homozygous IFNG genotype also
was significantly associated with the presence of CMV
copies in blood (0.53 vs 0.24; P5 .025).
When examined 100 days post-HSCT, patients ho-
mozygous for the 13-CA-repeat genotype had a similar
Biol Blood Marrow Transplant 15:1296-1305, 2009 1301IFNG Genotype, Proportion of CD41 Cells, and CMV Reactivationproportion ofCD41 lymphocytes as thosewith another
type of allele constellation (13.5%6 1.45%vs 18.1%6
1.51%ofCD41 lymphocytes;P5 .154).Thus, the low-
IFNG production genotype (ie, homozygotes for the
13-CA-repeat allele) did not influence the proportion
of CD41 lymphocytes in the blood.
Compared with recipients with other IFNG geno-
types and $ 10% CD41 lymphocytes, those with two
13-CA-repeat alleles (IFNG 3/3 genotype) and with\
10% CD41 lymphocytes had a significantly higher
number of CMV copies (8547 6 3628 vs 929 6 756
CMV copies/105 cells; P5 .002) (Figure 1B) and inci-
dence of reactivation (0.78 vs 0.18; P\ .001). Factorial
ANOVA was used to assess whether homozygosity for
the 13-CA-repeat genotype and a low proportion of
CD41 lymphocytes might act in a synergistic fashion.
The test showed that both factors were synergistic
with respect to the number of CMV DNA copies
(P 5 .015) during reactivation, but that the 2 factors
appeared to act independently regarding the incidence
of reactivation.
Patients homozygous for IFNG 13-CA repeats
were more frequently positive for CMV copies regard-
less of whether 10 copies (0.50 vs 0.38; P5 not signif-
icant [NS]) or 100 copies per 105 cells was considered.
However, statistical significance was attained only at
the 100-copy threshold value, (0.50 vs 0.26; P 5
.039). A low proportion of CD41 lymphocytes consti-
tuted a risk factor for CMV reactivation at levels of 10
copies/105 cells (0.38 vs 0.14; P 5 .013) as well as 100
copies/105 cells (0.62 vs 0.21; P 5 .001).
Gancyclovir given to decrease the risk of reactiva-
tion in patients receiving ATG did not affect the CMV
reactivation rate with a high number of CMV DNA
copies at later stages post-HSCT (0.31 vs 0.25; P 5
NS). Gancyclovir given as a preemptive treatment
did not affect the frequency of CMV reactivation,
which was usually noted before the treatment (0.38
vs 0.13; P 5 NS).
In univariate analysis, CMVpositivity at the level of
$ 100 DNA copies/105 cells was significantly associ-
ated with IFNG polymophism, aGVHD grade $ II,
presence of negative IgG serology in the donor or
recipient, and HLA mismatch (Table 2). All of these
variables were included inmultivariate analysis in addi-
tion to the following factors known to affect transplan-
tation outcome: conditioning regimen, type of donor
(matched sibling vs MUD), and female-to-male trans-
plantation [15-18]. Multivariate logistic regression
analysis showed that only homozygosity for the
13-CA-repeat genotype (odds ratio [OR] 5 0.221;
P5 .044), CD41 lymphocyte level\10% in the blood
lymphocyte population (OR 5 0.276; P 5 .050), and
donor–recipient HLA mismatch (OR 5 15.19; P 5
.006) played significant and independent roles in
CMV reactivation with a high number of copies in
patients post-HSCT (Table 3).DISCUSSION
In the present study, CMV reactivation occurred
in 30% of the patients, and the number of CMV
DNA copies in these patients was in the range of 100
per 105 cells from 31 to 60 day post-HSCT. Similar
data have been reported by Kim et al. [19], Ljungman
et al. [20], Cortez et al. [21], Schulenburg et al. [22],
and Busca et al. [23]. Our finding that patients with
low percentages and numbers of CD41 lymphocytes
were at increased risk for CMV reactivation also is in
agreement with previous reports [24-26]. Conse-
quently, our patient cohort behaved as expected with
respect to the presence of and risk factors for CMV
reactivation and thus was well suited for investigating
unknown factors that might act in concert with known
factors in contributing to CMV reactivation.
Viral copies were examined in the cellular pellet,
which has a high clinical utility [27]. Comparative
studies of plasma, whole blood, and leukocyte pellet
have found a significantly lower level of CMV copies
in plasma than in cell-containing samples [27-29];
thus, our study based on blood pellet nuclear cell
examination better reflects the risk of CMV disease,
demonstrating the actual number of copies residing
in blood cells.
IFNG plays a crucial role in mounting an immune
response against CMV [26,30,31]. The production of
this cytokine depends on the number of cells able to
respond to a given antigen and also is influenced by
the polymorphic features of the IFNG gene that mod-
ulate the rate of transcription. In this study, we found
that patients with CMV reactivation were more likely
to have a genotype composed of alleles characterized
by 13 CA repeats (IFNG 3/3 genotype) in the polymor-
phic region of the first intron of the IFNG gene.
Indeed, it has been shown that the specific number of
microsatellite repetitions can influence the rate of
transcription [32-36].
The association between the number of CA repeats
within the first intron of the IFNG gene and IFNG
generation potential was originally described by Pravica
et al. [7,8]. These authors reported that the allele with
12 CA repeats was associated with high IFNG gener-
ation potential. They also proposed a correlation
between the 12-CA allele and a T nucleotide at posi-
tion 1874, in contrast to alleles having more than 12
repeats with A at this position. According to Pravica
et al. [7,8], the presence of T, but not A, facilitates
NFkB binding, thereby enhancing transcription.
Any interpretation of the association between gene
polymorphic features and cytokine generation is usually
complex, because the polymorphism can influence cyto-
kine production directly or indirectly because of linkage
disequilibrium with other known or unknown genetic
factors. In an earlier study, we found that patients with
sarcoidosis who had the tumor necrosis factor-alpha
Table 3. Multivariate Analysis of Risk Factors for CMV Reactivation
Factor b coefficient OR 95% CI P value
Recipient IFNG genotype Homozygous 13-CA-repeat genotype
versus other 21.509 0.221 0.0496-0.987 .044
aGVHD grade $ II Lack of aGVHD or aGVHD grade I 0.560 1.751 0.488-6.279 .382
versus aGVHD grade $ II
Conditioning regimen RIC versus myeloablative 20.066 0.936 0.275-3.180 .914
Type of donor Sibling versus MUD 21.036 0.355 0.075-1.682 .185
Donor–recipient serology mismatch Mismatch versus match 0.737 2.090 0.518-8.438 .293
HLA mismatch Mismatch versus match 2.721 15.195 2.103-109.818 .006
Recipient sex Male versus female 20.971 0.379 0.114-1.262 .108
Donor–recipient sex Matched or male to female versus
female to male 0.638 1.893 0.471-7.609 .361
CD4+ lymphocytes <10% versus $10% 21.287 0.276 0.075-1.013 .049
Negative b coefficients for factors corresponding with IFNG genotype (b15 -1.509) and the percentage of CD4
+ cells (b85 -1.287) and positive b co-
efficients for HLA mismatch (b65 -2.721) show that IFNG genotypes other than the 13-CA-repeat homozygous genotype, as well as a high percentage
($ 10%) of CD4+ lymphocytes and HLA donor–recipient matching, decrease the risk of CMV reactivation. The ORs of these factors shows that the
probabilities of CMV infection in patients lacking the IFNG 13-CA-repeat homozygous genotype, having $ 10% of CD4+ cells, or being HLA matched
(at the allele level) are decreased 4.5, 3.6, or 15.2 times, respectively.
1302 Biol Blood Marrow Transplant 15:1296-1305, 2009E. Jaskula et al.(TNFA) 2 allele [37] weremore susceptible to symptoms
ofLo¨fgren’s syndrome.This allele correlateswith higher
TNFA production [38], but because of its strong linkage
disequilibrium with HLA-A1 B8 DRB1*03 [39], it may
be indirectly associated with low IFNG production
[5,6]. The role of IFNG polymorphism in this disease
was subsequently documented by findings demonstrat-
ing that the 13-CA-repeat IFNG genotype (3/3) is
a risk factor for Lo¨fgren’s symptoms in patients with sar-
coidosis [40]. This shows that the 13-CA-repeat homo-
zygous genotype is associated with a disease in patients
with sarcoidosis characterized by low IFNG production
[41]. Interestingly, only the IFNG 3/3 genotype, not al-
leles with more than 12 CA repeats, is associated with
symptoms of Lo¨fgren’s syndrome [40]. If Pravica et al.
[7,8] are correct, then all patients with more than 12
CA repeats should behave in a manner similar to those
having an A nucleotide at position 1874, which, they
postulate, is responsible for low IFNGgenerationpoten-
tial. In the present study, the risk of CMV reactivation
was associated with the IFNG 13-CA-repeat homozy-
gous genotype, but not with other microsatellite geno-
types having A at position 1874. Thus, the presence of
13 repeats is associated with clinical situations known
to be linked to low IFNG production. Similar observa-
tions came from our previous study, in which the 13-
CA-repeat homozygous genotype (IFNG 3/3 genotype),
but not 13/14, 13/15, or 14/14CA repeats, was prevalent
in patients with chronic GVHD (cGVHD) [42]. It is
known that IFNG knockout mice develop aGVHD
[43]; therefore, IFNG is not needed forGVHDmanifes-
tation, and a hypothetically low IFNGproduction geno-
type may facilitate cGVHD symptoms by making the
host more susceptible to infections. Indeed, 13-
CA-repeat homozygous patients undergoing HSCT
were found to experience more frequent Epstein-Barr
virus (EBV) reactivation than their counterparts with
other constellations of CA microsatellite alleles [44].
Our observation regarding CMV reactivation agreeswell with previous findings in individuals homozygous
for the13-CA-repeat allele andpossibly lackingadequate
IFNG production. Thus, these patients are susceptible
to diseases in which low IFNG production facilitates
CMV reactivation. Indeed, Miyake et al. [9] showed
that cells homozygous for the 13-CA-repeat allele pro-
duce significantly lower amounts of IFNG compared
with cellswithothernumbersofCArepeats.Findings re-
ported by Abbott et al. [45] are in line with the hypothe-
sized clinical relevanceof thehomozygous 13-CA-repeat
genotype as amarker for lowIFNGgenerationpotential.
These authors found that CA microsatellite polymor-
phism is associated with total serum IgE, and that a clin-
ically relevant immune response to hepatitis B virus
(HBV) is of greater significance than1874 T to A sub-
stitution. Thus, we postulate that microsatellite profile
is important in shaping a successful immune response
to CMV, similar to observations made with EBV and
HBV [44,45].
Our present findings are especially noteworthy
because the IFNG gene profile of the host represents
a risk factor for CMV reactivation early post-HSCT.
This also was observed with respect to the risk of
aGVHD [13]. Interleukin (IL)-6, IL-10, transforming
growth factor (TGF)-beta1, IL-2, and TNFA poly-
morphisms in the recipient also have been found to
influence the risk of aGVHD [46-50]. Thus, host poly-
morphisms of some cytokine genes are important to
HSCT outcome. Our interpretation of these findings
is that the recipient IFNG genotype acts at the pre-
transplantation stage, making the host more suscepti-
ble to CMV subclinical reactivation associated with
an increase in viral load. CMV IgG seropositivity in
patients reflects the presence of primary infection,
and further reactivations may result from one of the
risk factors of post-HSCT reactivation [51,52].
Our finding of an association between the disparity
in CMV serology in donor–recipient pairs and the
risk of CMV infection may be interpreted as follows:
Biol Blood Marrow Transplant 15:1296-1305, 2009 1303IFNG Genotype, Proportion of CD41 Cells, and CMV Reactivation(1) A recipient, if positive, harbors CMV in a latent
phase because of a primary infection, and the negative
donor transplant material lacks memory cells specific
to CMV [53]; and (2) a negative recipient lacks the
immune system competence for CMV, which facili-
tates reactivation of the virus present in the transplant
material [54]. Thus, reactivation is poorly controlled
in these 2 situations. Indeed, patients receiving a trans-
plant from a CMV-negative donor and CMV-negative
patients receiving a transplant from a CMV-positive
donor suffer more frequently from CMV reactivation
(Table 2).
This putative high viral load in patients with the
low–IFNG production genotype is associated with
a higher incidence and number of CMV copies when
the patients have a low CD41 lymphocyte fraction
and number. Another point that merits discussion is
the lack of association between donor IFNG genotype
(individual data not shown) and the risk of CMV reac-
tivation. We presume that the immune system impair-
ment post-HSCT results from immunosuppression,
and that the alloreactive hit is so severe that the weight
of genetic factors influencing IFNG production are
not strong enough to be valid in this situation.
The present study contributes to the literature of
CMV reactivation in patients post-HSCT with the
novel observation regarding the role of the homozy-
gous 13-CA-repeat IFNG genotype of the host and
the proportions of CD41 lymphocytes post-HSCT
in CMV reactivation at a clinically significant level.
Indeed, we found that patients with $ 100 CMV
DNA copies suffered more frequently from treat-
ment-related complications. A low proportion of
CD41 lymphocytes is the sole factor in CMV reactiva-
tion, recognized as the presence of any number of
CMV copies. IFNG genotype influences the pace of
viral replication, which is significantly associated
with a peak number of CMV DNA copies exceeding
100 per 105 peripheral blood cells. Thus, both factors
act independently (see multivariate analysis), addi-
tively favoring the pace of replication.
The value of 100 copies per 105 cells was chosen to
delineate a threshold value predictive ofCMV reactiva-
tion–associated complications, including GVHD,
relapses, and infections. The latter 2 complications
likely are from the immunosuppressive potential of
the CMV reactivation–associated process [55-57].
We found that a low proportion of CD41 lymphocytes
favors early reactivation events, but IFNG genotype
influences the incidence of reactivation with a high
number of copies; thus, low IFNGproducersmore fre-
quently have$ 100 CMV copy numbers per 105 blood
cells. This level was found to be a threshold for clini-
cally apparent complications that could be attributed
directly or indirectly to CMV reactivation.
The hypothesis that IFNG genotype facilitates viral
replication is also supported by the positive associationbetween 13-repeat homozygosity and the presence
of prolonged viremia. Determining the IFNG geno-
type before transplantation may help tailor viral sur-
veillance measures post-HSCT, thereby preventing
life-threatening complications associated with and
facilitated by CMV.ACKNOWLEDGMENTS
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